All News
A Multidimensional Approach in the Management of Axial Spondylarthritis
There has been much focus on the pharmacologic management of axSpA. Despite optimal control of inflammation, symptoms of fatigue and pain can persist. Long term use of analgesics including opioids carries significant risks. Strategies to improve response to treatment in this population is critical.
Read Article
Rheumatology Roundup: ACR22
On Thursday, November 21, 2022, Dr. Arthur Kavanaugh and Dr. Jack Cush reviewed the best and most interesting data and sessions presented at ACR22 in Philadelphia, PA. These are the research abstracts discussed:
Read Article
A Year in Review
Dr. Jack Cush reports on highlights from this annual session - featuring Drs. Carol Langford and John Varga as discussants. #ACR22
https://t.co/RcBKzt50ky https://t.co/nyDHX9vqzz
Links:
Dr. John Cush RheumNow ( View Tweet)
Differences in Presentation and Outcomes of Early vs Late Onset PsA
Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies
https://t.co/Bw3RHp3lSR https://t.co/Yva84Iw8hk
Links:
Dr. John Cush RheumNow ( View Tweet)
What's Happening on the Hill?
Dr. Rachel Tate ( @uptoTate) talks with Dr. Angus Worthing about #ACR22 Convergence Session # 12S119 about legislative updates.
https://t.co/zd6SVtSqrc https://t.co/7Y8ylkTSbx
Links:
Dr. John Cush RheumNow ( View Tweet)
Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor
Dr. Sims ( @DrCassySims) discusses abstract 0199 presented at #ACR22.
https://t.co/L14WoimRE6 https://t.co/LhgyE1LwGa
Links:
Dr. John Cush RheumNow ( View Tweet)
RA Topic Panel
RheumNow recaps the best & most interesting data presented at #ACR22 in RA. Panelists: Drs.Conway, Najm, Liew, Pope, Segan
Follow: @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan
https://t.co/6SAlQwcPS0 https://t.co/kSZgTQs6Ns
Links:
Dr. John Cush RheumNow ( View Tweet)
Infections in pre-RA: a cause or a consequence?
Dr. Aurelie Najm ( @AurelieRheumo) discusses oral presentation abstract #0535 from #ACR22.
https://t.co/ajI2zo4KRA https://t.co/cHkzNshVcn
Links:
Dr. John Cush RheumNow ( View Tweet)
Proposed Cancer Screening for Inflammatory Myositis Patients
11/12's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.
https://t.co/uMhJu6eQt1 https://t.co/JeeeGadP4d
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Appraisal, Praise & Critique
Dr. Cush talks ACR22, the highs and the lows.
https://t.co/NoRqvFaBKl https://t.co/0b5IlAojVq
Links:
Dr. John Cush RheumNow ( View Tweet)
Exciting Data for SLE: Plenaries from #ACR22
Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22.
https://t.co/e6tCwLdHMS https://t.co/u7yoE4T9Zs
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual target blockade may be better than one in SLE
Dr. Yusof ( @Yuz6Yusof) discusses abstracts #L07 and #1001 presented at #ACR22.
https://t.co/0SzQAorzZy https://t.co/fZ6CpFNSWI
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Topic Panel
Join RheumNow to recap the best and most interesting data presented at #ACR22 in the area of SLE.
Panelists: @KDAO2011 @bella_mehta @Yuz6Yusof @ericdeinmd @EBRheum @RHEUMarampa @Janetbirdope
https://t.co/7oUZcQK27U https://t.co/1JClivUJpk
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 ACR/EULAR Classification Criteria for GCA
Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA.
https://t.co/FL9FGhWcxB https://t.co/JKi7Nn4O2O
Links:
Dr. John Cush RheumNow ( View Tweet)
Avoid Abatacept in RA patients with a history of cancer?
Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22.
https://t.co/1lC33XlBt7 https://t.co/ttUQaTVF43
Links:
Dr. John Cush RheumNow ( View Tweet)
Anifrolumab shows long-term promise in patients with lupus
Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus.
https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx
Links:
Dr. John Cush RheumNow ( View Tweet)
Effect of voclosporin in class V lupus nephritis
Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
https://t.co/sH04dhBskS https://t.co/mUOrJKdYBF
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 - Day 1
https://t.co/GlEhTnKXm7 https://t.co/JFyMSpjFq3
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK vs TNF inhibitor Infections in RA
Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
https://t.co/ipD5ON7BJ7 https://t.co/rRD5wqHhFk
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Appraisal, Praise & Critique
Dr. Cush talks ACR22, the highs and the lows.
https://t.co/1SVr2LLOcG https://t.co/PqcMix7O1f
Links:
Dr. John Cush RheumNow ( View Tweet)
